Novartis to manufacture CureVac’s Covid-19 vaccine candidate CVnCoV
Novartis will manufacture the mRNA and bulk drug product for up to 50 million doses of the CVnCoV…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Mar 21
Novartis will manufacture the mRNA and bulk drug product for up to 50 million doses of the CVnCoV…
18 Feb 21
The companies initially signed an agreement in April 2020 to discover and develop new therapies for coronaviruses
11 Feb 21
Crestor is a statin, a lipid-lowering medicine intended to treat blood lipid disorders and prevent cardiovascular events, such…
08 Feb 21
Under the agreement, CureVac will initially supply 50 million doses of multi-variant Covid-19 vaccines to the UK with…
05 Feb 21
SAZ hospitals will use Philips solutions for patient monitoring and self-management
04 Feb 21
GSK will assist in the production of up to 100 million doses of CureVac’s first-generation Covid-19 vaccine CVnCoV…
28 Jan 21
GSK will transfer the production of the RTS,S antigen to Bharat Biotech, while it will retain the manufacturing…
20 Jan 21
The research and license collaboration aims to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody…
13 Jan 21
VIR-7832 is the second monoclonal antibody from Vir-GSK collaboration, and the study is expected to commence in Q1…
12 Jan 21
The collaboration will help Novartis expand its oncology portfolio with late-stage PD-1 for monotherapy and potential PD-1 combinations